SAM
DNLI icon

Smartleaf Asset Management’s Denali Therapeutics DNLI Stock Holding History

Smartleaf Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7K Hold
1,107
– – ﹤0.01% 1822
2026
Q1 		$20K Sell
1,107
-206
-16% -$4.1K ﹤0.01% 1959
2025
Q4 		$21.5K Buy
1,313
+359
+38% +$6.06K ﹤0.01% 1986
2025
Q3 		$13.9K Buy
954
+500
+110% +$7.18K ﹤0.01% 1973
2025
Q2 		$6.4K Sell
454
-19
-4% -$267 ﹤0.01% 1974
2025
Q1 		$6.99K Sell
473
-592
-56% -$11.3K ﹤0.01% 2067
2024
Q4 		$21.6K Buy
1,065
+399
+60% +$10.2K ﹤0.01% 1601
2024
Q3 		$19.6K Buy
666
+190
+40% +$4.71K ﹤0.01% 1354
2024
Q2 		$10.9K Buy
+476
New +$9.14K ﹤0.01% 1365

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's DNLI Position: Q2 2026 in Review

Smartleaf Asset Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 1,107 shares worth $28.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

Smartleaf Asset Management first reported a position in DNLI in Q2 2024 and has held it in 9 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Smartleaf Asset Management held 1,107 shares of Denali Therapeutics worth $28.7K as of Q2 2026.
  • Smartleaf Asset Management left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1822 holding.
  • Smartleaf Asset Management first reported a position in Denali Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.